Income Taxes (Details Narrative) - Chemomab Therapeutics Ltd [Member] - USD ($) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Operating loss carryforwards | $ 192,000,000 | $ 176,000,000 |
| Unrecognized tax benefits | $ 0 | |
| Income Tax Jurisdiction, Foreign [Member] | ||
| Statutory tax rate | 21.00% | |
| ISRAEL | ||
| Statutory tax rate | 23.00% |
| X | ||||||||||
- Definition Percentage of domestic federal statutory tax rate applicable to pretax income (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of unrecognized tax benefits. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|